Spatial density and diversity of architectural histology in prostate cancer: influence on diffusion weighted magnetic resonance imaging.

Multiparametric MRI (mpMRI) digital pathology prostate cancer architecture

Journal

Quantitative imaging in medicine and surgery
ISSN: 2223-4292
Titre abrégé: Quant Imaging Med Surg
Pays: China
ID NLM: 101577942

Informations de publication

Date de publication:
Feb 2020
Historique:
entrez: 20 3 2020
pubmed: 20 3 2020
medline: 20 3 2020
Statut: ppublish

Résumé

To assess the influence of specific histopathologic patterns on MRI diffusion characteristics by performing rigorous whole-mount/imaging registration and correlating histologic architectures observed in prostate cancer with diffusion characteristics in prostate MRIs. Fifty-two whole-mount pathology blocks from 15 patients who underwent multiparametric MRI (mpMRI) at a single institution prior to radical prostatectomy were retrospectively analyzed. Regions containing individual morphologic patterns (N=21 patterns, including variations of cribriforming, expansile sheets, single cells, patterns of early intraluminal complexity, and mucin rupture patterns) were digitally annotated by an expert genitourinary pathologist. Distinct tumor foci on each slide were also assigned a Gleason grade and scored as having any high-risk histologic pattern. Digital sections were aligned to MRI using a patient-specific mold and registered using local mean weighted piecewise transformation based on anatomic control points. Density and presence of morphological patterns was correlated to apparent diffusion coefficient (ADC) signal intensity using mixed effects model accounting for nested intra-foci, intra-patient correlation. Influence of intra-tumoral heterogeneity was assessed by affinity propagation clustering (APC) of morphology features and correlated to foci- and cluster-level ADC metrics. One hundred eleven distinct tumor foci were evaluated. Beta diversity, reflecting average morphology representation across inter- and intra-foci areas, demonstrated higher intra-tumor diversity within high-risk foci (P<0.05). ADC signal demonstrated an inverse correlation with foci-level Gleason grade (P>0.05), which was strengthened in cluster-level analysis for intra-foci regions containing high-risk morphologies (P=0.017). In voxel-based analysis, dense regions demonstrate lower ADC, but the presence and density for each morphology influenced ADC independently (ANOVA P<0.001). Architectural features influence ADC characteristics of MRI, with more complex tumors having lower ADC values regulated by presence and density of specific morphologies.

Sections du résumé

BACKGROUND BACKGROUND
To assess the influence of specific histopathologic patterns on MRI diffusion characteristics by performing rigorous whole-mount/imaging registration and correlating histologic architectures observed in prostate cancer with diffusion characteristics in prostate MRIs.
METHODS METHODS
Fifty-two whole-mount pathology blocks from 15 patients who underwent multiparametric MRI (mpMRI) at a single institution prior to radical prostatectomy were retrospectively analyzed. Regions containing individual morphologic patterns (N=21 patterns, including variations of cribriforming, expansile sheets, single cells, patterns of early intraluminal complexity, and mucin rupture patterns) were digitally annotated by an expert genitourinary pathologist. Distinct tumor foci on each slide were also assigned a Gleason grade and scored as having any high-risk histologic pattern. Digital sections were aligned to MRI using a patient-specific mold and registered using local mean weighted piecewise transformation based on anatomic control points. Density and presence of morphological patterns was correlated to apparent diffusion coefficient (ADC) signal intensity using mixed effects model accounting for nested intra-foci, intra-patient correlation. Influence of intra-tumoral heterogeneity was assessed by affinity propagation clustering (APC) of morphology features and correlated to foci- and cluster-level ADC metrics.
RESULTS RESULTS
One hundred eleven distinct tumor foci were evaluated. Beta diversity, reflecting average morphology representation across inter- and intra-foci areas, demonstrated higher intra-tumor diversity within high-risk foci (P<0.05). ADC signal demonstrated an inverse correlation with foci-level Gleason grade (P>0.05), which was strengthened in cluster-level analysis for intra-foci regions containing high-risk morphologies (P=0.017). In voxel-based analysis, dense regions demonstrate lower ADC, but the presence and density for each morphology influenced ADC independently (ANOVA P<0.001).
CONCLUSIONS CONCLUSIONS
Architectural features influence ADC characteristics of MRI, with more complex tumors having lower ADC values regulated by presence and density of specific morphologies.

Identifiants

pubmed: 32190560
doi: 10.21037/qims.2020.01.06
pii: qims-10-02-326
pmc: PMC7063286
doi:

Types de publication

Journal Article

Langues

eng

Pagination

326-339

Informations de copyright

2020 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: The authors have no conflicts of interest to declare.

Références

Genome Biol. 2005;6(5):R47
pubmed: 15892875
Radiology. 2011 Feb;258(2):488-95
pubmed: 21177390
Am J Clin Pathol. 2011 Jul;136(1):98-107
pubmed: 21685037
J Urol. 2017 Aug;198(2):316-321
pubmed: 28163032
Radiology. 2008 Dec;249(3):900-8
pubmed: 19011187
Int J Comput Assist Radiol Surg. 2016 Apr;11(4):657-66
pubmed: 26337442
J Urol. 2018 Jan;199(1):106-113
pubmed: 28728994
Am J Surg Pathol. 2016 Nov;40(11):1439-1456
pubmed: 27635949
Invest Radiol. 2009 Sep;44(9):572-6
pubmed: 19692841
Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1179-1187
pubmed: 29908785
J Med Imaging (Bellingham). 2018 Jan;5(1):011004
pubmed: 29098169
J Pathol. 1996 Nov;180(3):295-9
pubmed: 8958808
Urology. 1994 Jan;43(1):60-6; discussion 66-7
pubmed: 8284886
Radiology. 2015 Dec;277(3):751-62
pubmed: 26110669
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Radiology. 2017 Oct;285(1):147-156
pubmed: 28582632
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Rev Sci Instrum. 2009 Oct;80(10):104301
pubmed: 19895076
Radiology. 2018 Mar;286(3):918-928
pubmed: 29117481
JAMA. 2015 Jan 27;313(4):390-7
pubmed: 25626035
J Cell Biol. 2010 May 31;189(5):777-82
pubmed: 20513764

Auteurs

Stephanie A Harmon (SA)

Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, MD, USA.
Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

G Thomas Brown (GT)

Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, MD, USA.
National Library of Medicine, National Institutes of Health, Bethesda, MD, USA.

Thomas Sanford (T)

Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Sherif Mehralivand (S)

Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Joanna H Shih (JH)

Division of Cancer Treatment and Diagnosis: Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Sheng Xu (S)

Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Maria J Merino (MJ)

Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Peter L Choyke (PL)

Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Peter A Pinto (PA)

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Bradford J Wood (BJ)

Center for Interventional Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Jesse K McKenney (JK)

Department of Anatomic Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.

Baris Turkbey (B)

Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Classifications MeSH